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Abstract
Background: Staphylococcus aureus bacteremia is a common and serious infection worldwide and although treatment
guidelines exist, there is little consensus on optimal management. In this study we assessed the variation in management
and adherence to treatment guidelines of S. aureus bacteremia.
Methodology/Principal Findings: We prospectively recorded baseline clinical characteristics, management, and in-hospital
outcome of all adults with S. aureus bacteremia treated consecutively over one year in eight centres in the United Kingdom,
three in Vietnam and one in Nepal. 630 adults were treated for S. aureus bacteremia: 549 in the UK (21% methicillin-
resistant), 80 in Vietnam (19% methicillin-resistant) and 1 in Nepal. In the UK, 41% had a removable infection focus (50%
intravenous catheter-related), compared to 12% in Vietnam. Significantly (p,0.001) higher proportions of UK than
Vietnamese patients had an echocardiogram (50% versus 28%), received more than 14 days antibiotic therapy (84% versus
44%), and received .50% of treatment with oral antibiotics alone (25% versus 4%). UK centres varied significantly (p,0.01)
in the proportions given oral treatment alone for .50% of treatment (range 12–40%), in those treated for longer than 28
days (range 13–54%), and in those given combination therapy (range 14–94%). 24% died during admission: older age, time
in hospital before bacteremia, and an unidentified infection focus were independent predictors of in-hospital death
(p,0.001).
Conclusions/Significance: The management of S. aureus bacteremia varies widely between the UK and Vietnam and
between centres in the UK with little adherence to published guidelines. Controlled trials defining optimal therapy are
urgently required.
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Introduction
Staphylococcus aureus bacteremia (SAB) is one of the most common
serious bacterial infections worldwide. Its importance is well
recognised in high income countries and over recent years much
effort has been expended on disease surveillance and prevention,
particularly for infections caused by methicillin-resistant S. aureus
(MRSA). Despite this, S. aureus is the commonest cause of
bloodstream infections in the US with the highest mortality[1].
In the UK there are more than 12,000 cases of SAB each year[2],
of which around 30% die[3].
Recent studies from South East Asia have also documented S.
aureus as a significant and under-recognised cause of community
and hospital-acquired sepsis[4,5,6,7]. These studies suggest similar
clinical manifestations of SAB to high income countries, with
MRSA causing a considerable burden of disease, but mortality
may be higher[4]. There are, however, few data comparing
treatment and outcomes following SAB in these different settings.
Current treatment guidelines suggest that SAB should be
treated with prolonged intra-venous (IV) therapy: a minimum of
14 days for those with uncomplicated disease, and 4–6 weeks for
those with a deep focus of infection[8,9,10,11]. A penicillinase-
stable beta-lactam antibiotic (e.g. flucloxacillin, oxacillin, nafcillin)
is recommended to treat methicillin-susceptible SAB; and a
glycopeptide (e.g. vancomycin or teicoplanin) is recommended
for MRSA infections, or if the patient is intolerant of beta-lactams.
Combination therapy (e.g. beta-lactam/glycopeptide plus genta-
micin or rifampicin) is generally not recommended in these
guidelines, except in severe MRSA infections (e.g. endocarditis,
prosthetic joint infections). These recommendations, however, are
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based on data from fewer than 1500 patients randomised in 16
controlled trials. Much current practice is therefore based on
clinical experience and observational studies. Recent surveys of
European and US physicians have revealed diverse opinions
concerning optimal SAB management[12,13,14] and there is
some evidence of substantial practice variation within these
regions[15,16].
Our aim was to document the clinical characteristics,
management, and in-hospital outcome of adults with SAB across
8 centres in the UK, 3 in Vietnam and 1 in Nepal to investigate
the degree of practice variation across the centres, adherence to
current treatment guidelines, and baseline factors predicting
outcome.
Results
Data were recorded on 657 consecutive adults diagnosed with S.
aureus bacteremia. In 27 (4%), the isolate was considered a
contaminant (1 from Vietnam and 26 from the UK). All
subsequent analyses are based on the remaining 630 patients:
549 from the UK (1 centre had 3 patients, 7 had 49–150); 80 from
Vietnam and 1 from Nepal.
Patients in Vietnam/Nepal were younger, more likely to be
intra-venous drug users (IDU), had longer duration of symptoms,
were less likely to have an IV catheter-related infection and more
likely to have endocarditis than UK patients (table 1).
Twenty-one percent (95% confidence interval (CI) 18–25%) of
isolates from the UK were methicillin-resistant compared with
19% (11–29%) from Vietnam/Nepal. The range among UK
centres was 17% to 26% (p= 0.81). The extended antibiotic
susceptibility profiles for all the isolates are given in table 2.
Infection focus: identification and removal
Information on focus of infection was available for 617 (98%)
patients (table 1). Removable foci were removed in 92% of cases,
a median of 2 days (inter quartile range (IQR) 0–4 days) from the
first positive blood culture. Focus removal occurred before or on
the same day as the blood culture in 33%, after 1–2 days in 31%,
3–6 days in 18%, 7–13 days in 11%, and after 2 weeks in 7%.
There was no significant variation between the UK centres in the
timing of focus removal (table 3).
Echocardiogram
Echocardiography was performed in 50% (264/527) of patients
in the UK compared to 28% (23/81) in Vietnam/Nepal
(p,0.001) (table 3). Data on the use of trans-oesophageal
echocardiography, or the influence echocardiography on treat-
ment decisions, were not recorded. 59% of UK patients with a
focus which was not IV catheter-related but considered remov-
able, had an echocardiogram; compared to 50% with a non-
removable focus, 45% with an IV catheter-related infection, and
46% with no focus established (p= 0.13).
Start and choice of antibiotic treatment
Active anti-staphylococcal antibiotic treatment was given to
99% (593/601) of patients. Eight were not treated, either because
they had died (n= 4) or were discharged (n = 4) before treatment
was started. 81% of patients were treated before or within 1 day of
when the positive blood culture was taken; this proportion was
similar in the UK and Vietnam/Nepal, but differed between UK
centres (table 3).
Flucloxacillin was used to treat MSSA bacteremia in a similar
proportion in the UK (85%) and Vietnam/Nepal (81%), but
varied from 68% to 98% among UK centres (p = 0.003) (table 4).
A glycopeptide was given in 89% (62/70) of cases of MSSA
bacteremia who did not receive flucloxacillin. The reasons for not
using flucoloxacillin/other beta-lactams in these patients were not
recorded. Flucloxacillin was used empirically, before susceptibility
test results, in 18% of MRSA bacteremia in the UK and 86% (12/
14) in Vietnam/Nepal.
The antibiotic treatment of MRSA bacteremia varied substan-
tially in the UK. Teicoplanin was never used by two centres, but
was prescribed to most patients with MRSA bacteremia in two
others (7/10 and 18/20 cases, respectively). Linezolid was used to
treat 6/12 MRSA bacteremias in one centre, but never used (0/
30) in another.
Route of administration
Nearly all patients (98%) treated were given IV antibiotics for
some or all of their treatment. Fourteen patients (13 from UK)
were given oral antibiotics alone; all had MSSA bacteremia, 6 had
uncomplicated soft tissue infections, 5 had IV catheter-related
infections, 1 had bone infection, and two had no established focus
of infection. 11/14 received oral flucloxacillin alone, 5 for less than
14 days, and all survived to discharge.
Patients were excluded from the duration of treatment analysis
if they died during antibiotic therapy or within 2 days of stopping
therapy (n= 108, 82% treated for ,14 days), or if antibiotic start/
stop dates were missing (n = 56). Among the remaining 429
patients, 49% (183/377) of patients in the UK received oral
antibiotics exclusively for some part of their treatment, and 25%
for more than half of their total treatment time (figure 1; table 3).
In comparison, 6% (3/52) of cases in Vietnam/Nepal were treated
with exclusively oral treatment at some point during therapy.
Duration of antibiotic therapy
Of the 429 patients who started antibiotic treatment and did not
die on or within 2 days of stopping therapy, 16% in the UK
received ,14 days of therapy (oral or IV) compared to 56% in
Vietnam/Nepal (table 3). In the UK, 34% received ,14 days of
IV therapy, with significant variation between centres (range 10–
56%, p,0.001).
In the UK, duration of therapy varied by focus of infection
(p,0.001). The median days on therapy was 16 (IQR 14–19) for
IV catheter-related infections; 22 (IQR 15–40) for infections
caused by other removable foci; 27 (IQR 15–46) for non-
removable infections; and 16 (IQR 13–26) if the focus was not
established. The proportions receiving $28 days of therapy within
each of these respective groups was 13%, 38%, 45% and 18%
(figure 1). There was substantial variation between UK centres in
the proportion on $28 days therapy (table 3), with differences
remaining when restricted to patients with a focus which was
removable but not catheter-related, or not removable (range 21%
(8/39) to 60% (9/15); p = 0.03). Patients with no established focus
were treated longer if they had MRSA bacteremia (median 24
days (IQR 14–36), n = 11) than MSSA bacteremia (15 days (13–
22), n = 39; p = 0.03). In Vietnam/Nepal, the median duration of
therapy was 13 days (IQR 6 to 22), with only 8% (4/52) treated for
$28 days.
Combination antibiotic therapy
Forty-eight percent of patients were treated at some point with
combined use of two or more antibiotics. The proportion receiving
combination therapy was similar for the UK (48%) and Vietnam/
Nepal (47%), but varied substantially from 14% to 94% among
UK centres (table 3). The proportion on combination therapy
was similar for MRSA and MSSA bacteremia (43% and 48%,
respectively; p = 0.37), but varied according to the focus.
S. aureus Bacteremia Treatment
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Combination therapy was used more if the focus was not
removable (132/242, 55%), compared to either IV catheter-
related infections (45/111, 41%), removable focus (not catheter-
related) infections (50/112, 45%), or if a focus was not established
(51/121, 42%) (p = 0.03). The choice of combination therapies
used is summarised in table 5.
Table 1. Baseline characteristics of patients enrolled, by country (N= 630).
Factors1 United Kingdom N=549 Vietnam/Nepal N=81 p-value
MRSA bacteremia 116 (21%) 15 (19%) 0.62
Male gender 355 (65%) 58 (72%) 0.23
Age at positive culture (years) Median (IQR) 63.7 (46.9–77.3) 35.6 (27.0–54.1) ,0.001
,40 years 91 (17%) 48 (59%) ,0.001
40–59 years 146 (27%) 16 (20%)
60–79 years 198 (37%) 15 (19%)
$80 years 104 (19%) 2 (2%)
Intravenous drug use 54 (10%) 21 (26%) ,0.001
Diabetes mellitus 111 (21%) 11 (14%) 0.11
Immune suppression2 236 (47%) 30 (38%) 0.15
Days from admission to positive blood culture:
Before/same day 269 (50%)3 29 (36%) 0.004
1–2 days after 92 (17%) 19 (23%)
3–6 days after 48 (9%) 23 (28%)
7–13 days after 55 (10%) 5 (5%)
$14 days after 78 (14%) 5 (6%)
Duration of symptoms before positive blood culture:
#24 hours 209 (48%) 1 (1%) ,0.001
.24–72 hours 125 (29%) 12 (17%)
.72 hours 101 (23%) 58 (82%)
Focus of infection:4
Intra-venous catheter alone 113 (21%) 3 (4%) ,0.001
Other source of infection, and removable5 110 (20%) 6 (8%)
Not removable6 213 (40%) 38 (48%)
Not established 101 (19%) 33 (41%)
Whether site was infected:7
Central venous catheter 116 (22%) 3 (4%) ,0.001
Peripheral line 37 (7%) 2 (2%) 0.12
Implanted vascular device 10 (2%) 0 (0%) 0.37
Native heart valve 18 (4%) 12 (15%) ,0.001
Prosthetic heart valve 3 (1%) 1 (1%) 0.43
Native joint 26 (5%) 4 (5%) 0.99
Prosthetic joint 10 (2%) 0 (0%) 0.37
Vertebral bone 15 (3%) 2 (3%) 0.99
Other bone 17 (3%) 1 (1%) 0.49
Soft tissue 175 (34%) 24 (30%) 0.47
Thrombophlebitis 29 (6%) 1 (1%) 0.16
1Values in parentheses are percentages of total with information available, unless otherwise stated. Column percentages may not sum to 100% due to rounding.
Number of patients with missing data: susceptibility to methicillin (10), gender (1), age at positive culture (10), IV drug use (24), diabetes (31), immune suppression (51),
days from admission to positive blood culture (7), duration of symptoms before positive blood culture taken (124).
2Defined as any intrinsic (e.g. malignancy, chronic liver or kidney failure) or extrinsic (e.g. drugs) factor which might attenuate immune response as judged by the
treating physician.
315 patients had date of positive blood culture before date of admission.
4Excludes 11 patients without any information available on foci of infection, and 2 patients with foci of infection given (prosthetic heart valve and prosthetic joint) but
not known if considered removable.
5Whether or not the focus was removable was judged on a case-by-case basis by the attending physician. There was no study-wide definition.
63 patients had intra-venous catheter related infection which, in the individual clinical circumstances, were not considered removable.
7Information was sought on whether individual sites were infected. The proportion of patients with a given site infected was based on those with information available.
Patients could have more than one site infected.
doi:10.1371/journal.pone.0014170.t001
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Adherence to current treatment guidelines
Treatment guidelines suggest that uncomplicated SAB should
be treated with a minimum of 14 days antibiotics; those with a
deep focus of infection (complicated infection) should receive 4–6
weeks of antibiotic therapy[8,9,10,11]. In the UK, 74/94 (78.7%)
of patients with uncomplicated SAB (defined as IV catheter-
related, with prompt removal of the catheter and no other
infection focus identified) received treatment which adhered to
these guidelines (i.e. $14 days antibiotic therapy), although only
38.6% (72/186) with a deep, irremovable focus of infection
received $28 days of antibiotic treatment. In Vietnam/Nepal 3
patients had uncomplicated SAB and one received $14 days
antibiotic therapy; only 8.7% (4/46) of patients with complicated
infection received $28 days of treatment.
Combination therapy is only recommended for severe MRSA
infections, but was given to 47.8% (32/67) of patients with a deep
irremovable MRSA infection, 52.6% (132/251) with a deep
irremovable MSSA infection, and 41% (45/111) of all uncompli-
cated SAB secondary to a removed IV catheter.
Outcome: metastatic complications and hospital
discharge
Sixty seven (11%) patients (of 612) developed an additional site
of infection, secondary to the primary focus and after the start of
treatment; 18/129 (14%) with MRSA and 48/477 (10%) with
Table 2. Antibiotic susceptibility test results of S. aureus
isolates.
Antibiotic susceptibility1 MRSA MSSA
Penicillin susceptible 0/131 (0%) 83/483 (17%)
Erythromycin susceptible 39/120 (33%) 393/462 (85%)
Gentamicin susceptible 112/126 (89%) 468/480 (98%)
Fucidic acid susceptible 95/113 (84%) 370/407 (91%)
Rifampin susceptible 125/127 (98%) 434/436 (99%)
Tetracycline susceptible 110/117 (94%) 403/423 (95%)
Ciprofloxacin susceptible 20/122 (16%) 415/444 (93%)
Mupirocin susceptible 81/88 (92%) 262/269 (97%)
Vancomycin susceptible 122/122 (100%) 444/444 (100%)
Teicoplanin susceptible 61/61 (100%) 207/211 (98%)
Linezolid susceptible 89/89 (100%) 316/316 (100%)
1Denominator variation is due to differences between centres in tests being
performed routinely.
doi:10.1371/journal.pone.0014170.t002
Table 3. Comparison of factors relating to management of SAB between UK and Vietnam/Nepal, and between UK centres.
Number of
patients
enrolled
(N=630) Percentage (95% confidence interval) of patients
Underwent
echocardiogram1
Treated before
or within 1
day of positive
culture2
Received oral
antibiotics
exclusively for
.50% of time
on treatment3
Treated for
,14 days with
oral or IV
therapy3
Treated for
$28 days with
oral or IV
therapy3
Received
combination
therapy if
treated4
Removable
focus removed
before or within
2 days of
positive culture
Region
UK 549 50% (46–54%) 81% (77–84%) 25% (21–30%) 16% (13–20%) 32% (27–37%) 48% (43–52%) 59% (52–66%)5
Vietnam/Nepal 81 28% (19–40%) 86% (76–93%) 4% (0–13%) 56% (41–70%) 8% (2–19%) 47% (35–59%) - 5
P-value comparing
UK vs Vietnam/
Nepal
,0.001 0.33 ,0.001 ,0.001 ,0.001 0.86
UK centres6
1 89 47% (36–58%) 79% (69–87%) 28% (17–40%) 26% (16–39%) 26% (16–39%) 51% (40–62%) 58% (41–74%)
2 49 40% (26–55%) 92% (80–98%) 27% (14–43%) 12% (4–26%) 34% (20–51%) 94% (83–99%) 80% (52–96%)
3 150 53% (45–62%) 88% (82–93%) 16% (9–24%) 17% (10–25%) 38% (29–48%) 40% (32–48%) 66% (51–79%)
4 77 63% (51–75%) 82% (71–90%) 19% (9–34%) 17% (7–31%) 31% (18–47%) 45% (33–57%) 48% (31–66%)
5 57 37% (24–51%) 58% (44–72%) 12% (2–30%) 8% (1–25%) 54% (33–73%) 51% (37–65%) 41% (22–61%)
6 71 49% (36–61%) 76% (64–85%) 40% (28–53%) 13% (6–23%) 13% (6–23%) 14% (7–25%) 62% (47–76%)
7 53 55% (40–68%) 82% (69–92%) 39% (24–57%) 13% (4–28%) 42% (26–59%) 67% (52–80%) 67% (35–90%)
P-value comparing
UK centres
0.06 ,0.001 0.003 0.28 0.002 ,0.001 0.15
1Excludes 22 patients missing information on whether had an echocardiogram.
2Excludes 29 patients missing information on active anti-staphylococcal antibiotic treatment, and 2 patients missing date started treatment.
3Based on 429 patients with duration of treatment recorded, excluding those who died on treatment or within 2 days of stopping therapy.
4Excludes 6 patients known to have been treated but were missing information on whether received combination therapy.
5217/223 patients in the UK with removable focus had information on whether focus was removed, and if removed, date of removal recorded. Information on whether
focus was removed was available for 7 of the 9 patients in Vietnam/Nepal with removable focus, with focus removed within 2 days of positive culture in 4 patients.
6Excludes 1 UK centre with 3 patients enrolled.
doi:10.1371/journal.pone.0014170.t003
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Table 4. Antibiotics given for the treatment of SAB at any time during treatment, including early empirical treatment (N= 5781).
Antibiotics
2
MRSA MSSA
UK (N=105) Vietnam/Nepal (N=14) UK (N=402) Vietnam/Nepal (N=57)
Flucloxacillin 19 (18%) 12 (86%) 340 (85%) 46 (81%)
Vancomycin 71 (68%) 10 (71%)3 88 (22%) 19 (33%)
Teicoplanin 41 (39%) 0 (0%) 61 (15%) 0 (0%)
Linezolid 15 (14%) 0 (0%) 12 (3%) 0 (0%)
Rifampin 22 (21%) 1 (7%) 62 (16%) 3 (5%)
Aminoglycoside 22 (21%) 2 (14%) 71 (18%) 11 (19%)
Fucidic acid 6 (6%) 0 (0%) 40 (10%) 0 (0%)
Clindamycin 3 (3%) 0 (0%) 43 (11%) 0 (0%)
1Excludes 15/593 patients known to have been treated but information missing on antibiotics received (n = 10) or susceptibility to methicillin (n = 5, all received
flucloxacillin).
2Of 578 with information on antibiotics received, between 1–4 had missing information on whether they received an antibiotic. Antibiotics other than those listed were
given to 81/578 (15%) patients. The most commonly used were a fluoroquinolone (n = 28, 5%) and doxycycline (n = 12, 2%). Daptomycin and tigecycline were used
once.
3The 4 patients not treated with vancomycin either died (n = 1) or were discharged (n = 3) within 24 hours of the positive blood culture.
doi:10.1371/journal.pone.0014170.t004
Figure 1. Duration on any therapy and proportion of time treated spent on oral therapy exclusively (N=4291). 1 Excludes patients who
died on therapy or within 2 days of stopping
doi:10.1371/journal.pone.0014170.g001
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MSSA bacteremia (susceptibility to methicillin was unknown in
one patient). The commonest were lungs (n = 14, 21%) and soft
tissues (n = 14, 21%), followed by native heart valves (n = 11, 16%)
and bones/joints (n = 11, 16%). Metastatic infections developed in
14% (16/114) with an IV catheter-related infection, 15% (17/113)
with a removable but non-IV catheter-related infection, 10% (25/
249) with a non-removable focus of infection, and 7% (9/134) of
those with no established focus. A metastatic focus of infection
occurred more commonly in younger patients (p = 0.003) and in
IDU (23% in IDU versus 9% non-IDU, p= 0.002).
The cumulative probability of hospital discharge by 14 and 30
days after positive blood culture was 28% (95% CI 24–32%) and
55% (51–59%) respectively. The estimated proportion discharged
by 30 days was 42% (95% CI 33–50%) for MRSA bacteremia and
60% (95% CI 55–64%) for MSSA bacteremia.
Outcome: inpatient mortality
Twenty-four percent (139/587) died during admission. Forty-
five (32%) deaths occurred within 3 days of positive culture, 55
(40%) after 4–14 days, 35 (25%) after 15–60 days and only 4 (3%)
after .60 days. 58% (80/139) of deaths were considered by the
attending physicians to be directly attributable to SAB, similar for
MRSA (62%) and MSSA (56%) bacteremia. All but one of the 16
deaths in Vietnam/Nepal were attributable to SAB compared to
around half in the UK (65/123).
Risk of mortality varied significantly by focus of infection, being
highest among patients with an undefined focus (table 6;
figure 2). Death was also associated with older age and increasing
duration from admission to positive blood culture. After
adjustment for these factors we found no evidence of differences
between patients with MRSA and MSSA bacteremia, nor between
UK versus Vietnam/Nepal (table 6).
Discussion
Opinions regarding the optimal treatment of SAB are divided
[12], but the effects of this uncertainty on clinical practice and
patient outcome are unknown. SAB is becoming increasingly
important in lower income countries, but there is even less
information available from these regions[20].
We found patients with SAB in Asia (predominantly Vietnam)
were younger and more likely to be IDU and have endocarditis,
than those in the UK, who were more likely to have IV catheter-
related infections. These differences suggest a higher proportion of
SAB in Vietnam/Nepal were community-acquired (not recorded
in our study). The proportion of methicillin-resistant SAB was
similar in the UK (21%) and Vietnam/Nepal (19%). A recent
study from Thailand reported a higher proportion of methicillin-
resistant SAB (28%), of which 78% were considered hospital-
acquired[4], suggesting there may be substantial regional differ-
ences in the epidemiology of SAB in Asia. Further studies are
required to determine the epidemiology of invasive S. aureus
infections in this region.
Echocardiography is considered by some to be an essential
component of the clinical assessment of all SAB[21,22], yet was
performed in only 50% of cases in the UK and 28% in Vietnam/
Nepal. Echocardiography was performed in a surprisingly low
proportion (45%) of patients in whom no focus was established.
This may be explained by lack of availability in the Asian centres,
or by the death of patients before echocardiography and other
investigations could be performed (figure 2).
Failure to remove a removable infection focus is an independent
risk factor for SAB treatment failure[23,24]. 38% of infections
were secondary to a removable focus (of which approximately half
were IV catheter-related) and the proportion and speed of focus
removal did not differ significantly between centres. In contrast,
although the majority (81%) of patients started treatment within
one day of the positive culture being taken, this proportion varied
significantly between UK centres (table 3), as did the antibiotic
regimens used. Contrary to current guidelines [8,9,10,11], a third
of UK patients received ,14 days of intra-venous antibiotics, and
16% received ,14 days treatment by any route. This is consistent
with a recent survey of 266 European infection specialists: 35%
reported they would use antibiotics for 7 days or less for the
treatment of uncomplicated MRSA bacteremia and 10% said they
would consider oral antibiotics for the initial treatment of MRSA
bacteremia [12]. We found 25% of UK cases of SAB received
more than half their treatment exclusively by the oral route, which
varied from 12% and 40% between centres and that the
proportion was higher if the isolate was methicillin-susceptible.
Table 5. Combinations of antibiotics received by patients with MRSA and MSSA bacteremia at any time during treatment
(N= 2741).
Combination2
MRSA (N= 53) UK (N=49)
& Vietnam/Nepal (N=4) MSSA (N=221)
Overall UK(N=193) Vietnam/Nepal (N=28)
Beta-lactam + aminoglycoside3 4 (8%) 60 (27%) 51 (27%) 9 (32%)
Glycopeptide + aminoglycoside3 15 (29%) 32 (15%) 30 (16%) 2 (7%)
Beta-lactam + rifampin3 0 (0%) 34 (16%) 33 (17%) 1 (4%)
Glycopeptide + rifampin3 20 (38%) 32 (15%) 32 (17%) 0 (0%)
Beta-lactam + fucidic acid3 1 (2%) 33 (15%) 33 (17%) 0 (0%)
Glycopeptide + fucidic acid3 3 (6%) 6 (3%) 6 (3%) 0 (0%)
Other combinations 4 26 (50%) 99 (45%) 78 (41%) 21 (75%)
1Information on whether combination therapy was used was available for 587 of the 593 patients who were treated, of whom 279 (48%) received combination therapy.
Of these, 274 had information on susceptibility to methicillin.
272/274 (26%) of patients received more than one type of combination during the same episode.
3Information on whether a given combination was used was missing for 2–3 patients for each combination listed.
4112 received another 2-drug combination; 13 received 3 or more drugs in combination. Of the 112 who received a 2-drug combination 34 received a glycopeptide +
beta-lactam, 12 received a beta-lactam + fluoroquinolone, 12 received a beta-lactam + clindamycin, and 7 received a beta-lactam + macrolide. The remaining 47
received one of 22 different combinations.
doi:10.1371/journal.pone.0014170.t005
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The choice of antibiotics used to treat SAB varied according to
the susceptibility of the infecting organism, local preferences, and
availability. Vancomycin was the favoured first-line glycopeptide
for most cases of MRSA bacteremia, but two centres used
teicoplanin almost exclusively, and one used linezolid in half of
cases. Likewise, combination therapy was used to treat nearly all
patients (94%) in some centres but few (14%) in others, and the
choice of combinations varied widely. Similar proportions of
patients with MRSA and MSSA bacteremia received combination
therapy, but combinations were more likely to be used in patients
with a non-removable focus. Rifampin was rarely used in
Vietnam/Nepal, possibly because of the high prevalence of
tuberculosis in these countries and the dangers of developing
resistance in those with unsuspected active tuberculosis.
24% of patients died in hospital, which is similar to previous
reports[3,25], although just over half the deaths were directly
Table 6. Baseline factors associated with inpatient mortality following positive blood culture.
Factors
Number (%) died
during admission Univariable analyses1 Multivariable analyses1
Hazard Ratio
(95% CI) P-value
Hazard ratio
(95% CI) P-value
Overall 139/587 (24%)
Country:
UK 123/533 (23%) 1 0.21 1 0.15
Vietnam/Nepal 16/54 (30%) 1.42 (0.83–2.43) 1.60 (0.84–3.04)
Susceptibility to methicillin:
MSSA 100/456 (22%) 1 0.06 1 0.77
MRSA 37/125 (30%) 1.43 (0.98–2.07) 1.14 (0.77–1.69)
Gender:
Male 89/389 (23%) 1 0.56 1 0.94
Female 50/198 (25%) 1.11 (0.79–1.56) 1.01 (0.71–1.44)
Age at positive blood culture result:
,60 years 40/279 (14%) 1 1
60–79 years 59/200 (30%) 2.21 (1.48–3.30) 2.15 (1.43–3.23)
$80 years 40/101 (40%) 3.17 (2.05–4.92) ,0.001 2.98 (1.88–4.73) ,0.001
Intravenous drug use:
No 122/494 (25%) 1 1
Yes 14/74 (19%) 0.74 (0.43–1.29) 0.29 1.41 (0.72–2.75) 0.31
Diabetes mellitus:
No 107/448 (24%) 1 1
Yes 23/116 (20%) 0.81 (0.51–1.26) 0.35 0.67 (0.42–1.06) 0.09
Immune-suppression
No 70/290 (24%) 1 1
Yes 60/253 (24%) 0.99 (0.71–1.40) 0.97 0.97 (0.68–1.38) 0.86
Days from admission to positive blood culture:
Before/same day 55/306 (18%) 1 1
1–6 days 35/151 (23%) 1.31 (0.86–2.00) 1.42 (0.92–2.19)
7–13 days 21/54 (39%) 2.44 (1.48–4.02) 2.84 (1.72–4.71)
$14 days 28/76 (37%) 2.19 (1.41–3.42) 0.001 2.23 (1.37–3.62) ,0.001
Duration of symptoms before blood culture taken:
#24 hours 52/208 (25%) 1 1
25–72 30/133 (23%) 0.83 (0.54–1.27) 0.97 (0.62–1.52)
.72 26/140 (19%) 0.71 (0.45–1.13) 0.15 0.87 (0.50–1.53) 0.88
Focus of infection:
Intra-venous catheter related only, and removable 16/110 (15%) 1 1
Other source of infection, and removable 14/112 (13%) 0.86 (0.42–1.74) 1.06 (0.52–2.16)
Not removable 51/228 (22%) 1.64 (0.95–2.84) 2.05 (1.18–3.57)
Not established 58/130 (45%) 3.89 (2.26–6.69) ,0.001 4.17 (2.41–7.23) ,0.001
1Hazard ratios of inpatient mortality were estimated using competing risks method, with hospital discharge a competing risk. Missing data for covariates were imputed
using multiple imputation chained equation methods.
doi:10.1371/journal.pone.0014170.t006
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attributed to the infection. Case fatality was similar in the UK
(23%) and Vietnam/Nepal (30%), although the numbers of deaths
in the later could have been under-estimated by the tendency in
Vietnam for relatives to take seriously ill patients home to die.
Indeed, one Vietnamese centre was excluded from the analysis as
no in-patient deaths were recorded. Older age, an unidentified
focus of infection, and longer duration between admission and
bacteremia were independent risk factors for all-cause mortality
(table 6). Others have reported age and focus to be strongly
associated with outcome[24,25,26], but duration of admission
prior to bacteremia has not been previously linked to outcome.
This finding is likely explained by an association between
prolonged admission and increased co-morbid conditions, but
cannot be confirmed with the limited baseline clinical character-
istics recorded. There was a trend for methicillin-resistance to be
associated with in-hospital death by univariate analysis, but this
association was not sustained in the multivariable analysis; others
have reported similar findings[3,25,27] suggesting factors other
than antibiotic resistance are the strongest determinants of
outcome in MRSA bacteremia. In particular, we did not attempt
to associate variations in treatment practices (for example,
duration or route of antibiotic therapy) with outcome because of
the strong likelihood of selection bias influencing the results. Such
an analysis might produce misleading results with a potentially
dangerous influence on clinical practice (wrongly justifying short
or long durations of treatment, for example) and might obscure the
pressing need to address the major questions surrounding the
management of SAB through randomised controlled trials.
In summary, we have demonstrated that SAB is a serious
infection in the UK and Vietnam, associated with high in-hospital
mortality and significant variation in practice between the two
regions and between centres in the UK. Adherence to published
treatment guidelines was poor. In particular, a substantial
proportion of patients with SAB received less than the recom-
mended duration of therapy and antibiotic combinations were
used far more widely than recommended. Until such time as the
key questions in management have been addressed through large
randomised controlled trials, extensive variations in practice will
likely persist with uncertain consequences for patient care.
Materials and Methods
Clinical data were recorded prospectively on all adults (.15
years) with S. aureus isolated from one or more blood culture.
Patients were excluded if the blood isolate was mixed with another
pathogen. Organisms were identified and antibiotic sensitivity
testing performed according to standard methods by each centre’s
microbiology laboratory.
Data were collected between November 5th 2008 and
November 5th 2009 in 8 centres in the UK and 4 in Asia (3
Vietnam, 1 Nepal) (see acknowledgements). One centre (Cam-
bridge) joined the network in October 2009. All UK centres are
large National Health Service hospitals, which provide secondary
and tertiary referral care. Two centres in Vietnam (Hospital for
Tropical diseases, Ho Chi Minh City; National Hospital for
Tropical Diseases, Hanoi) provide secondary and tertiary referral
services for infectious diseases; the third (Bach Mai Hospital,
Hanoi) provides general medical facilities for the local population.
Patan Hospital, Kathmandu, Nepal, provides primary and
secondary healthcare facilities.
Physicians caring for the patients identified eligible patients and
entered individual, anonymized data via a commercial web-based
electronic data collection system (MACRO, InferMed limited, UK)
with a full audit trail. All data were held on a central secure server.
Data inconsistencies were monitored throughout the investigation
by the statistician and principal investigator and returned to the
centres for review and amendment if necessary.
The UK National Research Ethics Service reviewed the protocol
and deemed the investigation an evaluation of service, not requiring
review by an ethics committee. Each UK centre obtained
permission from their Medical Director to collect the data. Separate
permissions were obtained to undertake the investigation in
Vietnam and Nepal from the Oxford Tropical Research Ethics
Committee and the local institutional review boards.
Figure 2. Cumulative incidence of in-patient mortality from date of positive blood culture, by focus of infection. X-axis truncated at 60
days since there were only 4 deaths occurring after this time point.
doi:10.1371/journal.pone.0014170.g002
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Statistical analysis
We compared factors relating to the management of SAB
between regions, UK centres, focus of infection, and methicillin
susceptibility. Differences between groups were assessed using chi-
squared and Fisher’s exact tests for binary variables, and Wilcoxon
rank-sum and Kruskal-Wallis tests for continuous variables. Focus
of infection was pre-specified as related to a removable central/
peripheral intravenous catheter (without other source); related to
another removable focus (e.g. drainable soft tissue abscess,
removable medical device/prosthesis); related to an irremovable
focus (e.g. skin/soft tissue infection without abscess, native heart
valve, osteomyelitis); or the focus was not established. Patients who
died on therapy or within 2 days of stopping therapy were
excluded from analyses of duration of antibiotic therapy.
For analysis of inpatient mortality, only patients with date of
positive blood culture and date of discharge or death available
were included. One Vietnamese centre (27 patients) recorded no
inpatient deaths and was excluded from this analysis: it is common
practice for dying Vietnamese patients to receive terminal care
from their families at home and this information was not recorded.
When this occurred in the other Vietnamese centres, date of
discharge was recorded as date of death. Follow-up of patients was
considered from the date of positive blood culture until date of
death or date of discharge. Since inpatient mortality and hospital
discharge are competing events, applying standard survival
analysis methods could lead to biased results[17]. Therefore,
cumulative incidence of inpatient mortality and hospital discharge
and hazard ratios were estimated using competing risks meth-
ods[17,18]. The effects of the demographic and clinical factors at
baseline on inpatient mortality were assessed. To avoid excluding
patients with missing factors in regression models, missing data
were imputed using chained equation methods with 20 imputa-
tions[19]. All analyses were undertaken using STATA version 11
(STATA Corporation, Texas, USA).
Acknowledgments
Writing committee
Guy Thwaites (Chairman) (Imperial College, London, UK)
Trinh Duong (Statistician) (London School of Hygiene and Tropical
Medicine, London, UK)
Chanaka de Silva (Royal Liverpool University Hospital, Liverpool, UK)
Jonathan Edgeworth (Guy’s and St. Thomas’s Hospital, London, UK)
Susan Hopkins (Royal Free Hospital, London, UK)
John Klein (Guy’s and St. Thomas’s Hospital, London, UK)
Andrew Kirby (Royal Liverpool University Hospital, Liverpool, UK)
Martin Llewelyn (Brighton and Sussex Medical School, Brighton, UK)
Ho Dang Trung Nghia (Hospital for Tropical Diseases, Ho Chi Minh
City, Vietnam)
Matthew Scarborough (John Radcliffe Hospital, Oxford, UK)
Robert Tilley (Royal Devon and Exeter Hospital, Exeter, UK)
M. Este´e To¨ro¨k (Cambridge University Hospitals NHS Foundation
Trust, Cambridge, UK)
Sarah Walker (Medical Research Council Clinical Trials Unit, London,
UK)
Heiman FL Wertheim (Oxford University Clinical Research Unit,
Hanoi, Vietnam)
James Whitehorn (University College London Hospital, London, UK)
Peter Wilson (University College London Hospital, London, UK)
UKCIRG centres and investigators
1) Royal Liverpool University Hospital, Liverpool, UK: Chanaka de
Silva, Andrew Kirby, Nicholas Beeching, Chris Parry
2) John Radcliffe Hospital, Oxford, UK: Matthew Scarborough, Derrick
Crook, Tim Peto, Heather Godwin, Lily O’Connor
3) Brighton and Sussex University Hospitals, Brighton, UK: James Price,
John Paul, Martin Llewelyn
4) University College London Hospital, London, UK: James Whitehorn,
Steve Morris-Jones, Philip Gothard, Bruce Macrae, Peter Wilson
5) Royal Free Hospital, London, UK: Susan Hopkins, Giovanni Satta
6) Guy’s and St Thomas’s Hospital, London, UK: Jonathan Edgeworth,
John Klein, Carolyn Hemsley
7) Royal Devon and Exeter Hospital, Exeter, UK: Robert Tilley,
Stephen Glass, Marina Morgan
8) Cambridge University Hospitals NHS Foundation Trust, Cambridge,
UK: M. Este´e To¨ro¨k, Emma Nickerson, Theodore Gouliouris, Sani Aliyu,
Effrossyni Gkrania-Klotsas, Sharon Peacock, Fiona Cooke, Nick Brown,
Mark Farrington.
9) Oxford University Clinical Research Unit/Hospital for Tropical
Diseases, Ho Chi Minh City, Vietnam: Jeremy Farrar, Vinh Chau, To
Song Diep, Ho Dang Trung Nghia, Tran Tinh Hien,
10) Oxford University Clinical Research Unit, Hanoi, Vietnam: Heiman
Wertheim
11) National Hospital for Tropical Diseases, Hanoi, Vietnam: Nguyen
Van Kinh, Dao Tuyet Trinh, Nguyen Vu Trung, Pham Van Ca
12) Bach Mai Hospital, Hanoi, Vietnam: Doan Mai Phuong, Nguyen
Sam, Mai Lan Huong
13) Patan Hospital, Kathmandu, Nepal: Bhuhha Basnyat, Amit Ariyal,
Samir Koirala, Olita Shilpakar
We thank the staff from each microbiology laboratory who took part in
the study.
Author Contributions
Conceived and designed the experiments: GET. Performed the experi-
ments: GET. Analyzed the data: GET. Contributed reagents/materials/
analysis tools: GET. Wrote the paper: GET.
References
1. Shorr AF, Tabak YP, Killian AD, Gupta V, Liu LZ, et al. (2006) Healthcare-
associated bloodstream infection: A distinct entity? Insights from a large U.S.
database. Crit Care Med 34: 2588–2595.
2. Health Protection Agency. Communicable Disease Surveillance Centre DoH
(2009) Summary points and commentary on Quarterly (April 2006 to December
2008) and financial year (April 2006 to March 2008) MRSA bacteraemia data
derived from Mandatory Surveillance, March 2009.
3. Wyllie DH, Crook DW, Peto TE (2006) Mortality after Staphylococcus aureus
bacteraemia in two hospitals in Oxfordshire, 1997-2003: cohort study. BMJ 333: 281.
4. Nickerson EK, Hongsuwan M, Limmathurotsakul D, Wuthiekanun V,
Shah KR, et al. (2009) Staphylococcus aureus bacteraemia in a tropical setting:
patient outcome and impact of antibiotic resistance. PLoS One 4: e4308.
5. Nickerson EK, Wuthiekanun V, Wongsuvan G, Limmathurosakul D,
Srisamang P, et al. (2009) Factors predicting and reducing mortality in patients
with invasive Staphylococcus aureus disease in a developing country. PLoS One 4:
e6512.
6. Hoa NT, Diep TS, Wain J, Parry CM, Hien TT, et al. (1998) Community-
acquired septicaemia in southern Viet Nam: the importance of multidrug-
resistant Salmonella typhi. Trans R Soc Trop Med Hyg 92: 503–508.
7. Tran TS, Jamulitrat S, Chongsuvivatvong V, Geater A (1998) Postoperative
hospital-acquired infection in Hungvuong Obstetric and Gynaecological
Hospital, Vietnam. J Hosp Infect 40: 141–147.
8. Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr., Bolger AF, et al. (2005)
Infective endocarditis: diagnosis, antimicrobial therapy, and management of
complications: a statement for healthcare professionals from the Committee on
Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovas-
cular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and
Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed
by the Infectious Diseases Society of America. Circulation 111: e394–434.
9. Elliott TS, Foweraker J, Gould FK, Perry JD, Sandoe JA (2004) Guidelines for
the antibiotic treatment of endocarditis in adults: report of the Working Party of
the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother
54: 971–981.
10. Gemmell CG, Edwards DI, Fraise AP, Gould FK, Ridgway GL, et al. (2006)
Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococ-
cus aureus (MRSA) infections in the UK. J Antimicrob Chemother 57: 589–608.
11. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, et al. (2009) Clinical
practice guidelines for the diagnosis and management of intravascular catheter-
related infection: 2009 Update by the Infectious Diseases Society of America.
Clin Infect Dis 49: 1–45.
12. Dryden M, Andrasevic AT, Bassetti M, Bouza E, Chastre J, et al. (2010) A
European survey of antibiotic management of methicillin-resistant Staphylococcus
aureus infection: current clinical opinion and practice. Clin Microbiol Infect 16
Suppl 1: 3–30.
S. aureus Bacteremia Treatment
PLoS ONE | www.plosone.org 9 December 2010 | Volume 5 | Issue 12 | e14170
13. Naber CK, Baddour LM, Giamarellos-Bourboulis EJ, Gould IM, Herrmann M,
et al. (2009) Clinical consensus conference: survey on Gram-positive blood-
stream infections with a focus on Staphylococcus aureus. Clin Infect Dis 48 Suppl 4:
S260–270.
14. Hussain A, Alleyne S, Jenkins D (2010) A survey of attitudes towards methicillin-
resistant Staphylococcus aureus bacteraemias amongst United Kingdom microbiol-
ogists. J Antimicrob Chemother 65: 347–349.
15. Ammerlaan H, Seifert H, Harbarth S, Brun-Buisson C, Torres A, et al. (2009)
Adequacy of Antimicrobial Treatment and Outcome of Staphylococcus aureus
Bacteremia in 9 Western European Countries. Clin Infect Dis.
16. Wong V, Wariyar R, Weston V, Olver WJ, Youngs E, et al. (2010) Audit of
treatment of Staphylococcus aureus bacteraemia. Clinical Medicine 10: 266–269.
17. Tai BC, Peregoudov A, Machin D (2001) A competing risk approach to the
analysis of trials of alternative intra-uterine devices (IUDs) for fertility regulation.
Stat Med 20: 3589–3600.
18. Fine J, Gray R (1999) A proportional hazards model for the subdistribution of
competing risk. J Am Stat Assoc 94: 496–509.
19. Royston P (2004) Multiple imputation of missing data. Stata Journal 4: 227–241.
20. Nickerson EK, West TE, Day NP, Peacock SJ (2009) Staphylococcus aureus disease
and drug resistance in resource-limited countries in south and east Asia. Lancet
Infect Dis 9: 130–135.
21. Fowler VG, Jr., Li J, Corey GR, Boley J, Marr KA, et al. (1997) Role of
echocardiography in evaluation of patients with Staphylococcus aureus bacteremia:
experience in 103 patients. J Am Coll Cardiol 30: 1072–1078.
22. Sullenberger AL, Avedissian LS, Kent SM (2005) Importance of transesophageal
echocardiography in the evaluation of Staphylococcus aureus bacteremia. J Heart
Valve Dis 14: 23–28.
23. Fowler VG, Jr., Sanders LL, Sexton DJ, Kong L, Marr KA, et al. (1998)
Outcome of Staphylococcus aureus bacteremia according to compliance with
recommendations of infectious diseases specialists: experience with 244 patients.
Clin Infect Dis 27: 478–486.
24. Jensen AG, Wachmann CH, Espersen F, Scheibel J, Skinhoj P, et al. (2002)
Treatment and outcome of Staphylococcus aureus bacteremia: a prospective study of
278 cases. Arch Intern Med 162: 25–32.
25. Turnidge JD, Kotsanas D, Munckhof W, Roberts S, Bennett CM, et al. (2009)
Staphylococcus aureus bacteraemia: a major cause of mortality in Australia and New
Zealand. Med J Aust 191: 368–373.
26. Lesens O, Hansmann Y, Storck D, Christmann D (2003) Risk factors for
metastatic infection in patients with Staphylococcus aureus bacteremia with and
without endocarditis. Eur J Intern Med 14: 227–231.
27. Melzer M, Eykyn SJ, Gransden WR, Chinn S (2003) Is methicillin-resistant
Staphylococcus aureus more virulent than methicillin-susceptible S. aureus? A
comparative cohort study of British patients with nosocomial infection and
bacteremia. Clin Infect Dis 37: 1453–1460.
S. aureus Bacteremia Treatment
PLoS ONE | www.plosone.org 10 December 2010 | Volume 5 | Issue 12 | e14170
